Pfizer Abrysvo — Revenues: decreased by 62.5% to $180.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.4%, from $131.00M to $180.00M.
pfe_segment_abrysvo_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $375.00M | $515.00M | $145.00M | $56.00M | $356.00M | $198.00M | $131.00M | $143.00M | $279.00M | $480.00M | $180.00M |
| QoQ Change | — | — | — | — | — | — | — | — | +37.3% | -71.8% | -61.4% | +535.7% | -44.4% | -33.8% | +9.2% | +95.1% | +72.0% | -62.5% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | -5.1% | -61.6% | -9.7% | +155.4% | -21.6% | +142.4% | +37.4% |